registHER: Results from a prospective, longitudinal cohort study of women with HER2 positive metastatic breast cancer.

被引：0

作者：

Rugo, HS

Yardley, D

Tan-Chiu, E

Brufsky, A

Kaufman, P

Paik, S

Ulcickas-Yood, M

Mayer, M

Tripathy, D

机构：

[1] UCSF, Ctr Comprehens Canc, San Francisco, CA USA

[2] Sarah Cannon Canc Ctr, Nashville, TN USA

[3] Canc Res Network, Plantation, FL USA

[4] Univ Pittsburgh, Ctr Canc, Pittsburgh, PA USA

[5] Dartmouth Hitchcock Med Ctr, Lebanon, NH 03766 USA

[6] Galt Associates, Sterling, VA USA

[7] Univ Texas, SW Med Ctr, Dallas, TX USA

[8] NSABP, Pittsburgh, PA USA

来源：

BREAST CANCER RESEARCH AND TREATMENT | 2004年 / 88卷

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

引用

页码：S90 / S90

页数：1

共 50 条

[1] registHER: A prospective, longitudinal cohort study of women with HER2 positive metastatic breast cancer.
Tanchiu, E
Kaufman, PA
Paik, S
Ulcickas-Yood, M
Mayer, M
Tripathy, D
Rugo, H
Brufsky, A
JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) : 46S - 46S
[2] registHER: treatments and clinical outcomes from a prospective observational cohort study of patients with HER2-positive metastatic breast cancer.
Brufsky, A
Rugo, H
Tripathy, D
Kaufman, P
Mayer, M
Paik, S
Ulcickas-Yood, M
Yardley, D
Tan-Chiu, E
BREAST CANCER RESEARCH AND TREATMENT, 2005, 94 : S148 - S148
[3] registHER: An observational cohort study of patients with HER2+metastatic breast cancer
Yood, Marianne Ulcickas
Kaufman, Peter A.
Mayer, Musa
Rugo, Hope
Brufsky, Adam
Tan-Chiu, Elizabeth
Yardley, Denise
Paik, Soonmyung
Wang, Lisa
Birkner, Merrill
Brammer, Melissa
Tripathy, Debu
PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2008, 17 : S40 - S40
[4] Prospective Validation and Characterization of HER2 Positive Circulating Tumor Cells in Patients with HER2 Negative Metastatic Breast Cancer.
Olson, E. M.
Flores, L. M.
Najita, J. S.
Curley, C.
Jeong, J.
Murray, K.
Savoie, J. J.
Winer, E. P.
Krop, I. E.
CANCER RESEARCH, 2011, 71
[5] HER2 overexpressing metastatic breast cancer.
Spigel D.R.
Burstein H.J.
Current Treatment Options in Oncology, 2002, 3 (2) : 163 - 174
[6] Tolerability of neratinib in older adults with HER2 positive or HER2 mutated metastatic breast cancer.
Lee, Jin Sun
Yost, Susan Elaine
Stiller, Tracey
Blanchard, Suzette
Padam, Simran
Katheria, Vani
Tang, Aileen
Martinez, Norma
Patel, Niki Himat
Sedrak, Mina S.
Waisman, James Ross
Li, Daneng
Sanani, Shamel
Presant, Cary A.
Mortimer, Joanne E.
Yuan, Yuan
JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
[7] Prognostic nomogram for patients with non-metastatic HER2 positive breast cancer in a prospective cohort
Luo, Chuanxu
Zhong, Xiaorong
Wang, Zhu
Wang, Yu
Wang, Yanping
He, Ping
Peng, Qian
Zheng, Hong
INTERNATIONAL JOURNAL OF BIOLOGICAL MARKERS, 2019, 34 (01): : 41 - 46
[8] Trastuzumab and vinorelbine combination in the treatment of Her2 positive metastatic breast cancer.
Bayo, J
Mayordomo, JI
Sanchez-Rovira, P
Perez-Carrion, R
Illaramendi, J
Flores, EG
Bueno, JMG
Vazquez, MR
Crespo, C
Palomo, AG
Huelva, HJRJ
JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (14) : 67S - 67S
[9] registHER: patient characteristics and time course of CNS metastases in patients with HER2-positive metastatic breast cancer.
Yardley, D. A.
Kaufman, P. A.
Mayer, M.
Ulcickas, Yood M.
Tan-Chiu, E.
Brufsky, A. M.
Rugo, H. S.
Tripathy, D.
Brammer, M. G.
Paik, S.
BREAST CANCER RESEARCH AND TREATMENT, 2007, 106 : S263 - S264
[10] Correlation of trastuzumab treatment benefit with quantitative HER2 expression levels in HER2 positive metastatic breast cancer.
Bachmeier, Beatrice
Sperinde, Jeff
Weidler, Jodi Marie
Lie, Yolanda
Chenna, Ahmed
Winslow, John
Engel, Jutta
Schubert-Fritschle, Gabriele
Sommerhoff, Christian
Petropoulos, Christos J.
Bates, Michael Patrick
Huang, Weidong
Nerlich, Andreas
JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)

← 1 2 3 4 5 →